Ada Torres Vega

Ada Torres Vega serves as a primary procurement lead within the CDC Office of Acquisition Services, driving the acquisition of critical public health infrastructure and scientific capabilities. She manages complex contracting actions that enable laboratory diagnostics, biomedical research, and real-time disease surveillance systems essential to the CDC’s mission. Her portfolio centers on high-stakes, science-driven procurements requiring technical rigor, regulatory compliance, and rapid deployment—particularly in infectious disease response and clinical diagnostics. She works closely with scientific and operational teams to translate public health needs into actionable contract requirements, ensuring alignment with federal acquisition regulations and national preparedness priorities. Her key contractor relationships include leading providers of diagnostic technologies and public health services such as General Dynamics Information Technology, Inc., Cepheid, GlaxoSmithKline, LLC, New York City Health & Hospitals Corp, and MRIGLOBAL. These partnerships reflect a focus on integrated solutions spanning instrument manufacturing, in-vitro diagnostic reagents, and specialized testing services. Torres Vega fosters long-term, performance-based vendor relationships characterized by technical collaboration, compliance with biosafety standards, and scalability to meet surge capacity demands during public health emergencies. Torres Vega’s contracting activity is exclusively non-set-aside, with 100% of awards issued under full and open competition. This reflects a strategic emphasis on accessing the broadest possible pool of technical expertise and industrial capacity, prioritizing capability and readiness over socioeconomic categorization. While she does not routinely utilize 8(a), HUBZone, or SDVOSB set-asides, her procurement decisions are guided by merit-based evaluation criteria focused on technical merit, past performance, and operational resilience. Her primary procurement focus lies in NAICS 334516 (analytical laboratory instrument manufacturing), 325413 (in-vitro diagnostic substance manufacturing), and 541380 (testing laboratories and services), with additional emphasis on research and development in life sciences. She routinely procures next-generation sequencing platforms, molecular diagnostic kits, automated lab systems, and bioinformatics services, demonstrating deep expertise in clinical diagnostics, epidemiological data infrastructure, and laboratory modernization initiatives.